Impel Pharmaceuticals Inc. announced that Stephen Shrewsbury, M.D., current Chief Medical Officer, will depart from the Company effective March 31, 2023.
IPI Legacy Liquidation Co
Equities
IMPL
US45258K1097
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+21.85% | 46.44B | |
+38.62% | 39.1B | |
-8.05% | 38.76B | |
+29.04% | 31.24B | |
-13.75% | 25.8B | |
+10.65% | 25.9B | |
+38.43% | 13.12B | |
-6.92% | 11.32B | |
-12.29% | 10.68B |